UNI-EN 92:Notification from Rositsa Doneva in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 92 | / | 2024 | |||||||
Date of issue: | 2024-09-10 | ||||||||||
Short name of the issuer | |||||||||||
SOPHARMA AD | |||||||||||
Subject | |||||||||||
Notification from Rositsa Doneva in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | |||||||||||
Official market - legal basis | |||||||||||
art. 56. 1. 2 of Act on Public Offering. | |||||||||||
Unofficial market - legal basis | |||||||||||
Contents of the report: | |||||||||||
Notification from Rositsa Doneva in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | |||||||||||
Annexes | |||||||||||
File | Description | ||||||||||
RDoneva_Sopharma_EN_09092024.pdf RDoneva_Sopharma_EN_09092024.pdf | Notification from Rositsa Doneva in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD |
SOPHARMA AD | |||||||||||||
(fullname of the issuer) | |||||||||||||
SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
(short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
1220 | Sofia | ||||||||||||
(post code) | (city) | ||||||||||||
IlienskoShosse | 16 | ||||||||||||
(street) | (number) | ||||||||||||
+359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
(phone number) | (fax) | ||||||||||||
(e-mail) | (web site) | ||||||||||||
nd | |||||||||||||
(NIP) | (REGON) |
SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
Date | Name | Position / Function | Signature | ||
2024-09-10 | Ognian Donev | Executive director |
Cena akcji Sopharma AD
Cena akcji Sopharma AD w momencie publikacji komunikatu to 14.4003 PLN. Sprawdź ile kosztuje akcja Sopharma AD aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma AD.